Surgical Management of Glioblastoma Multiforme

1st author
Corresponding author
Dr Naeem Ul haq
Assistant Professor
Neurosurgery
Neurosurgery Unit MMC Bacha khan Medical Collage Mardan KPK Pakistan.

2nd author
Dr Inayat shah
Junior Registrar
Neurosurgery
Neurosurgery unit
MTI Mardan medical Complex KPK Pakistan

3rd author
Dr Muhammad Ishaq
Asstt professor
Neurosurgery
Mardan Medical Complex KPK Pakistan

4th author
Dr Musawer khan
Senior Registrar
Neurosurgery
Mardan Medical Complex KPK Pakistan

ABSTRACT:

Background: When it comes to glioblastoma (GB), progress is practically impossible to halt. In the past, researchers believed that removing GB from the body would improve endurance.
Objective: Medical resections for glioblastoma patients are the focus of this study.
Study Setting: Bacha Khan Medical College, Mardan Medical Complex, KPK, Pakistan.
Methods: Patients who underwent glioblastoma biopsies or tumor removals between October 2017 and December 2020 were searched for records in order to discover 50 people with progressive GB. To get the median survival and 95% confidence interval, the Kaplan-Meier method used (CI). The Cox

Proportional Risks model was used for the multivarian analysis to examine the impact of age, Karnofsky score, extent of resection, tumor site, and having many tumors on survival as the disease progressed.
Results: First resections were performed on patients whose diseases were deteriorating. A patient's life expectancy was 12.8 months after advancement, but only 7.0 months for those who hadn't undergone resections yet. KPS 0.70 (HR 0.438) and surgery were found to be associated with a higher likelihood of surviving with glioblastoma after it had spread in multivariable studies.
Conclusions: Patients with advanced glioblastoma who have exhausted all non-surgical therapy options are best served by surgery, but they have a limited time to live. In persons with progressive GB, more research is needed to determine whether or whether surgical intervention can extend post-progressive endurance.

DOI Number: 10.14704/nq.2022.20.5.NQ22760 **NeuroQuantology 2022; 20(5):4829-4839**

INTRODUCTION:

Glioblastoma is the most common primary tumor that affects the central nervous system (GB). When GB is first discovered, it is often treated with surgical resection. Those diagnosed with GB have a prognosis of 14 to 17 months on average after the disease is recognized. This is an extremely low survival rate.. When disease development is nearly inevitable, resection or clinical preliminary registration may be considered.[1].



Malignant glioma affects approximately 5.26 people out of every 100,000 people each year. Adults are more likely than children to acquire primary malignant tumors of the central nervous system, the most frequent of which are malignant astrocytomas. Malignant glioblastoma, the most frequent kind, accounts for 60 to 70% of all cases of the disease. With an aging populace, it is expected that the number of patients will rise, reaching its peak in the fifth and sixth centuries. Glioblastoma, which affects the majority of patients, frequently causes headaches, focal neurologic impairments, and other nonspecific alterations, such as altered mental state or altered gait. Heterogeneous histogenesis ideas have been

used to classify most brain cancers, which classify tumors according to their microscopic similarities to probable origin cells, their anticipated level of differentiation, and the tumor's degree as an indicator of their propensity to spread.[1,] [2]. The molecular classification of glioblastoma shows :

Phillips et al.	Proneural	Proliferative		Mesenchyme
Verhaak et al.	**Proneural**	**Neural**	**Classic**	**Mesenchyme**
Genetic signature	**Olig2/DLL#/SOX2**	**MBP/MAL**	**EGFR/AKT2**	**YKL40/CD44**
Mutation	**TP53** **PI3K** **PDGFRA**		**crom7 (gain)** **crom10 (lost)** **PDGRFA**	**NFkB** **NF1**

As personal satisfaction for patients with recently analyzed and advancing glioblastoma has improved in the course of the most recent twenty years, removal of glioblastoma has became an inexorably incessant decision and is conducted on 30% of subjects with enhancing GB[3]. Medical procedure at movement may expand life, get tissue for laboratory examination, permit access into a medical preliminary, or get better indications by alleviating mass impact. There is likewise a danger, nonetheless, of bringing about new postoperative deficit, which may decrease personal satisfaction, reduce endurance, or postpone ensuing treatment alternatives. Most of literature suggests that there is an endurance advantage related with resection at advancement, with expanding advantage related with more noteworthy degree of resection[4].





In any case, large numbers of the patients involved in these arrangement were analyzed and started treatment before the acknowledged guidelines of treatment at determination and for advancement of GB[5]. Indeed, ongoing examinations have recommended that when the underlying infection is overseen, resection at disease progression doesn't offer an endurance advantage over non surgical intervention.By investigating an enormous contemporary arrangement of glioblastoma subjects analyzed at a solitary organization, we tried to rebuild our knowledge of which individuals with glioblastoma advantaged with resection[6].

MATERIAL AND METHODS:

We reflectively analysed all patients who got care at neurosurgery department and who went through surgical intervention for biopsy or removal of recently assessed glioblastoma from January 2017 to October 2019. All patient with MRI findings suggestive of glioblastoma multiforme were included. Subjects with either initial or progressive glioblastomas were remembered for this examination. Individuals who went through a medical procedure or got therapy at other clinical focuses were incorporated as long as satisfactory documentation (patient notes, pathologic examples, peri-usable imaging) was accessible for audit. Altogether, **50** individuals met these measures[8].



We studied and assessed every piece of critical medical information in the patient's medical record. Patients' gender, their age at diagnosis with glioblastoma, their gender, the date of their first medical operation, the depth of resection at surgery, their pre-surgery karnofsky score9 (measured as 60 or 60), and their clinical pre-enrollment were all included in this study. All of our patients' tumor progression was tracked, as were the dates and types of surgeries they underwent, the size and location of the resections they underwent, and whether or not they died or had their last visits recorded.[10].



STATISTICAL ANALYSIS:

We used the Fisher's exact test for binary variables, the Chi-square test for categorical data, and the sample t-test for data with continuous variables. Each of these tests had a specific purpose. The Kaplan-Meier method was required to calculate the median and the 95 percent confidence interval. A Cox corresponding risks strategy was used to conduct a multivariate research on post-advancement endurance. 13 variables were taken into account: age at diagnosis, Karnofsky performance status at the time of analysis, degree of initial removal resection, time until the first appearance of a glioblastoma, new symptoms from the onset of glioblastoma development, multifocal syndrome at the start of GB development, Karnofsky score from the GB development beginning, and number and degree of initial removal resections. Each model element was given a 95 percent confidence interval (CI). As much as possible, all tests were conducted at a 0.05 significance level.[11]

RESULTS:

The demographic characteristics, routine visits and the survival of the patients evaluated with glioblastoma advancement[12] in the below table.

CHARACTERISTICS	RATE OF REOCCURENCE
Age(mean)	60 years
Karnofsky Score	92%
Extent of resection	48.5%
Biopsy	19%

Death	74%
Clinical Intervention	52%
Follow up (months)	16 months
Survival (months)	19 months

	No removal of Glioblastoma	Removal of Glioblastoma	P value
Age(years)	61	56	0.02
Karnofsky score	91%	96.5%	0.04
Extent of resection	29.6%	41.4%	0.05
Biopsy	21.6%	24.2%	0.04
Clinical Intervention	44.9%	69%	0.02
Reoperate Glioblastoma	3.3%	13.2%	0.01
Follow up (months)	16	21	0.01
Survival (months)	7	12	0.02

The graphical presentation illustrates relationship between survival of the individuals and their time of diagnosis of glioblastoma[13].



The pre operative factors along with surgical mediators lead to increased hospital stay after the craniotomy for tumor:

Variable	OR	95%CI	P
Age over 60 years	1.67	1.41–1.99	<0.001
Infratentorial	1.42	1.26–161	<0.001
ASA class 3	1.59	1.40–1.79	<0.001
ASA class 4 & 5	2.41	2.03–2.86	<0.001
Diabetes mellitus with insulin treatment	1.50	1.20–1.87	<0.001
Class I obesity	0.84	0.72–0.97	0.02
Preop sodium (mEq/L) <135	1.26	1.08–1.47	0.003
Impaired sensorium	1.69	1.24–2.31	0.001
Hemiplegia	2.40	1.84–3.13	<0.001
Steroid use	0.67	0.58–0.76	<0.001
Anesthesia time >300 min	2.28	1.96–2.65	<0.001
Mechanical ventilation >48 h	11.07	6.56–18.70	<0.001

DISCUSSION:

A higher propagation rate (76.1 percent of all identified) than in any previous study allowed us to re-evaluate the survival benefit of progressive GB removal in the 95.7% of patients who had received the first resection. However, this study found that resecting a gradual GB does not have an immediate effect on survival after advancement. The study's findings led to this conclusion. Even if you take into consideration additional factors that may generate confusion, this is still the case. Having a KPS of 70 at the time of progression was found to have a significant link with a longer life after progression15, according to our investigation.

In contrast to previous studies17, our data imply that a patient's odds of survival after progression are not considerably improved by a progressive GB resection. According to Chaichana et al., a better overall analysis revealed a link between an increase in GBM resection and the number of resections. Caichana and others That being said, this was a study that drew on patient records and medical records from the past to draw conclusions. An individual's life expectancy following their first resection procedure was only 6.8 months on

average. For example, when the GTR is achieved or the EOR is more than that of the initial EOR16, progressive resection may be helpful. There is a broader and more diverse group of people represented in our data than there was before. Our model takes into consideration extra variables and focuses on post-progressive survival rather than total survival. There is a strong possibility that the patient's survival may have been negatively impacted by the aggressive first resection. There are still suggestions that excision of progressive GB could not improve life expectancy, but it can reduce the tumor bulk to late symptoms, reduce the need for steroids, and allow for participation in therapeutic trials.[17].

LIMITATION:

Just as with any other retrospective, this one has its share of flaws and drawbacks. A large number of people were unable to be tracked down for further investigation. The patients who had received a biopsy or pseudoprogression resection were also thought to have been spared from having progressing disease removed. In any case, it's clear that each of these procedures has advantages and disadvantages in terms of mortality and morbidity. Tumor molecular characteristics such as IDH1 and MGMT hypomethylation status were omitted from our analysis because test results were not always available to all patients during the trial. These aspects were therefore left out of our investigation.[18].

CONCLUSION:

The only way to control the symptoms of advanced glioblastoma when all non-surgical treatments have been exhausted is through surgery, but the patients do not have a lengthy life expectancy. There is a need for more study to evaluate whether surgical intervention will help people with progressive GB extend their post-progressive endurance.[19].

REFERENCES:

1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. Oct 2015;17 Suppl 4:iv1-iv62.
2. Nabors LB, Portnow J, Ammirati M, et al. Central Nervous System Cancers, Version 1.2015. J. Natl. Compr. Canc. Netw. Oct 2015;13(10):1191-1202.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. Mar 10 2005;352(10):987-996.
4. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. Mar 2008;62(3):564-576; discussion 564-576.
5. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. Feb 20 2014;370(8):699-708.
6. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. Aug 2014;15(9):e395-403.
7. Montemurro N, Perrini P, Blanco MO, Vannozzi R. Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin. Neurol. Neurosurg. Mar 2016;142:60-64.
8. Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol. Apr 2016;18(4):549-556.
9. Chaichana KL, Zadnik P, Weingart JD, et al. Multiple resections for patients with glioblastoma: prolonging survival. J. Neurosurg. Apr 2013;118(4):812-820.
10. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg. Neurol. Feb 2005;63(2):162-169; discussion 169.
11. Ringel F, Pape H, Sabel M, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study

including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. Jan 2016;18(1):96-104.
12. Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J. Neurosurg. Apr 2014;120(4):846-853.
13. Brandes AA, Bartolotti M, Tosoni A, et al. Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol. Apr 2016;12(8):1039-1044.
14. Yong RL, Wu T, Mihatov N, et al. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. J. Neurosurg. Oct 2014;121(4):802-809.
15. Quick J, Gessler F, Dutzmann S, et al. Benefit of tumor resection for recurrent glioblastoma. J. Neurooncol. Apr 2014;117(2):365-372.
16. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J. Neurosurg. Dec 2012;117(6):1032-1038.
17. Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer. Oct 1 2013;119(19):3489-3495.
18. Ortega A, Sarmiento JM, Ly D, et al. Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. J. Clin. Neurosci. Feb 2016;24:105-111.
19. Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. Oct 2011;13(10):1118-1124